Related Experiment Video
Updated: May 12, 2026
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
Published on: September 5, 2017
FDG Uptake in WT1 Peptide Vaccination Adjuvant-induced Granuloma: A 93-month Follow-up
Yuka Onishi1, Tomoya Kotani, Taisei Kanayama
1Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
We report a woman in her 20s with alveolar rhabdomyosarcoma treated with Wilms tumor 1 (WT1) peptide vaccination administered as an investigational immunotherapy. Serial PET/CT demonstrated intense FDG uptake at the injection site with progressive skin thickening and calcification. Remarkably, FDG uptake continued to increase after vaccination cessation, peaking at 49 months before gradually declining. Unlike transient inflammation seen with conventional vaccines, WT1 vaccination induces prolonged FDG uptake due to the oil-based adjuvant Montanide, causing chronic inflammation and granuloma formation. Recognition of this characteristic course is essential to avoid misdiagnosis as cutaneous metastasis.
We report a woman in her 20s with alveolar rhabdomyosarcoma treated with Wilms tumor 1 (WT1) peptide vaccination administered as an investigational immunotherapy. Serial PET/CT demonstrated intense FDG uptake at the injection site with progressive skin thickening and calcification. Remarkably, FDG uptake continued to increase after vaccination cessation, peaking at 49 months before gradually declining. Unlike transient inflammation seen with conventional vaccines, WT1 vaccination induces prolonged FDG uptake due to the oil-based adjuvant Montanide, causing chronic inflammation and granuloma formation. Recognition of this characteristic course is essential to avoid misdiagnosis as cutaneous metastasis.
More Related Videos
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013